- Record: found
- Abstract: found
- Article: found
Finerenone Reduces Onset of Atrial Fibrillation in Patients with Chronic Kidney Disease and Type 2 Diabetes
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
<p class="first" id="d1159001e252">Patients with chronic kidney disease (CKD) and
type 2 diabetes (T2D) are at risk of
atrial fibrillation or flutter (AFF) due to cardiac remodeling and kidney complications.
Finerenone, a novel, selective, nonsteroidal mineralocorticoid receptor antagonist,
inhibited cardiac remodeling in preclinical models.
</p>